Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

It's completely natural for your vision to shift over time, but there are simple ways to keep your eyes in top shape.

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

Ophthalmologists specialize in wet AMD diagnosis and treatment. Learn about first steps toward diagnosis and treatment.

Emergen Research Logo The development of anti-VEGF therapies, which inhibit the growth of abnormal blood vessels in the retina, reduces the ...

Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

Biocon Biologics Ltd (BBL), the biosimilars company and subsidiary of Biocon Ltd, has announced a licence agreement with Regeneron to commercialise Yesafili, a drug used to treat ophthalmological ...